Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.

Published in: Alimentary pharmacology & therapeutics (2018)

Multiple treatment options are now available for patients with IBS-D. However, the safety profiles of these agents vary widely by number needed to harm value. Providers should consider both safety and efficacy of a specific intervention when determining how best to manage patients' IBS-D symptoms.

Keyphrases

irritable bowel syndrome
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
randomized controlled trial
prognostic factors
depressive symptoms
patient reported